News by subject: TRI

Sixteen weeks of omalizumab results in a higher tolerated threshold for multiple food allergies according to new research presented today at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and published in the New...

Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare...

PassPort Technologies, Inc. (PPTI), based in San Diego, initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort® platform technology. The study objectives are to evaluate...

Denver-based PCM Trials, the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina. EmVenio is the largest provider of...

Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant milestone in partnership with Eilean Therapeutics LLC: the successful completion of a single ascending dose Phase 1 clinical trial for lomonitinib, a selective...

Gene editing technology could revolutionize the treatment of genetic diseases, including those that affect the mitochondria?cell structures that generate the energy required for the proper functioning of living cells in all individuals. Abnormalities...

Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy...

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting -- -- Preclinical data for BLU-808, a...

Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in the Phase 3 SIERRA TrialThe results...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA)...

MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLOtm CADe version has been published in the prestigious Lancet Digital Health medical journal. The...

CSL Vifor and Travere Therapeutics, Inc., today announced that the European Medicines Agency's (EMA) CHMP has...

Immunofoco, a company dedicated to developing cell therapy products for solid tumors, announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered,...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced that Frank Stonebanks, Renibus' Co-CEO, and Bhupinder Singh, MD, Renibus'...

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company")  a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the MHRA has officially accepted...

A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID. The study, titled "Hyperbaric Oxygen...

IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, today announced the continued advancement of IGNX001, an IgG4 monoclonal antibody-based therapeutic candidate...

CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to provide advanced nucleic acid-based drug analytical services. CATUG, a distinguished global entity specializing in integrated...

~ Late-breaking presentation demonstrates that a repeat dose of NDS1C epinephrine nasal spray within five minutes safely increases epinephrine absorption by approximately 50 percent compared with a single dose ~ ~ Additionally, new pooled analyses...

Elevation Oncology, Inc. , an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has...

Inspiratm Technologies OXY B.H.N. Ltd. (the "Company" or "Inspira Technologies"), a breakthrough medical technology company targeting to supersede mechanical ventilators, has unveiled an exclusive in-house capability designed to simulate both the...

PolyBio Research Foundation today announced the second phase of its LongCovid Research Consortium (LCRC), including the distribution of $15M to fund research and clinical trials....

Introduction: In the realm of hyperpigmentation, the quest for more effective and safer options for prevalent and often stubborn...

MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLOtm CADe version has been published in the prestigious Lancet Digital Health medical journal....

Telix Pharmaceuticals Limited today announces its results for the financial year ended 31 December 2023. All figures are in AUD$ unless otherwise stated.[1] 2023 highlights Total Group revenue of $502.5M, an increase of 214% from $160.1M in 2022...

Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that clinical pharmacokinetic (PK) data on dose linearity and systemic exposure from the first study...

Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is...

STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig,...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the international multicenter Phase III clinical study of Cevira® (APL-1702), the non-surgical...

If approved, vorasidenib would be the first targeted therapy in IDH-mutant diffuse glioma, a malignant and incurable brain tumor In clinical studies, vorasidenib has demonstrated strong blood-brain barrier penetrance alongside clinically meaningful...

CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the...

Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant achievement in collaboration with Eilean Therapeutics LLC: the commencement of first-in-human trials for eiletoclax, a highly potent BCL2 inhibitor, within just...

Auditory Insight, a leading consultancy for the hearing healthcare industry, analyzes preliminary results for gene therapy clinical trials addressing deafness and hearing loss in its Q1 2024 Research Note. Download the Research Note: Gene Therapy...

Pelvital, the women's health MedTech company on a mission to transform the standard of care for...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology. This is the first...

As the life sciences industry continues to rapidly evolve, sponsors,...

NeuroSense Therapeutics Ltd. (Nasdaq:...

Decades of research reveal that maintaining high NAD+ levels significantly supports the body's ability to age well. Neurohacker Collective's new supplement, Qualia NAD+, demonstrated an 85% increase in NAD+ levels in a preliminary clinical...

Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of...

Aethlon Medical, Inc. , a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a...

Kazia Therapeutics Limited , a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial. This...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced the...

Armata Pharmaceuticals, Inc. ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D.,...

Q32 Bio Inc., a...

A team of researchers from Germany, the USA, the UK, and Norway won the third edition of the BIAL Award in Biomedicine, a 300,000 Euro prize promoted by the BIAL Foundation, which seeks to recognise a work in biomedicine of exceptional quality and...

Mallinckrodt plc, a global specialty pharmaceutical company, today announced a poster presentation of findings from a systematic literature review and meta-analysis of the...

Rejuvenate Biomed NV ("Rejuvenate Biomed"), a pioneering clinical-stage platform and pipeline company committed to enhancing lifelong health through innovative therapeutics, today announces breakthrough functional outcome results from its Phase 1b...

On February 19, 2024, the Journal of American Medical Association?Neurology (JAMA NEUROLOGY, IF: 29.0) published online the key findings of a phase III clinical study (NCT04950920) (the "TASTE-SL Study") investigating Sanbexin® (a combination of...

Everest Medicines (HKEX 1952.HK)'s licensing partner, Venatorx Pharmaceuticals announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam...